| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $62.9M | +699.0% |
| R&D Expense | $115.1M | +16.1% |
| SG&A Expense | $151.6M | +118.9% |
| Operating Income | -$213.1M | +64.0% |
| Interest Expense | $10.1M | — |
| Pre-tax Income | -$204.6M | +64.0% |
| Income Tax | $0 | — |
| Net Income | -$204.6M | +64.0% |
| EPS (Basic) | -$0.60 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $164.1M | +359.3% |
| Short-term Investments | $365.1M | -21.8% |
| Inventory | $11.4M | — |
| Current Assets | $571.5M | +8.6% |
| Total Assets | $594.8M | +10.0% |
| Current Liabilities | $82.2M | +41.2% |
| Long-term Debt | $47.2M | — |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$173.4M | -33.0% |
| Capital Expenditures | $8.0M | — |
| Investing Cash Flow | $99.5M | -18.9% |
| Financing Cash Flow | $202.5M | — |
| Free Cash Flow | -$181.4M | -39.1% |
| +71.6% |
| EPS (Diluted) | -$0.60 | +71.6% |
| Total Liabilities |
| $289.1M |
| +276.3% |
| Stockholders' Equity | $305.7M | -34.1% |